We evaluated glycohemoglobin (GHb) and glycated plasma protein (GPP) by automated affinity HPLC for their ability to monitor both short-term and long-term antecedent glycemia in 70 diabetic subjects. We placed 30 subjects on an intervention protocol in which insulin and (or) dietary changes were made twice weekly to acutely decrease glycemia. We monitored 40 subjects at 6-week intervals; changes in the clinical regimen were made at that time only. Despite weekly changes in mean blood glucose in the subjects who received more intensive intervention, GHb concentrations correlated significantly with the weekly (r = 0.66, P <0.001), 2-week(r = 0.70, P <0.001), 3-week (r = 0.72, P <0.001), and 6-week (r = 0.83, P <0.001) mean glucose concentrations. GPP correlated significantly with measured glycated albumin determined by boronate affinity columns (r = 0.83, P <.001) and correlated best with the 1-week (r = 0.66, P <0.001), 2-week (r = 0.64, P <.001) and 3-week (r = 0.60, P <0.001) mean antecedent glucose concentration. Thus, GHb, traditionally considered a marker for only long-term diabetic control, correlated significantly with both shortterm and long-term antecedent glycemia. assessment for all blood proteinsof interest with a single method. This may allow objective determination of antecedentglycemiccontrol for the previous 2-3 months (e.g., via GHb) and short-term diabetic control for the preceding 1-2 weeks [e.g., via glycatedplasma proteins (GPP), especially glycated albumin] in the same specimen.
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altered charge (e.g., HbS or HbC) by many glucose adducts comigrating with HbA1 species (e.g., carbamylated Hb), and by problems arising from artifacts induced under various storage conditions (9-13). The boronate affinity chromatography method involving minicolumns has been gaining wide acceptance because it is not affected by Hb variants, slight temperature changes, carbamylated Hb, the labile fraction (aldimine or Schiff base), or ionic strength of the buffer (9, 14-19). However, in some laboratories, precision has been a problem with these small columns. The application of HPLC used with affinity methods has markedly improved precision and run-time while maintaining the major advantage of the boronate affinity method (17-20): Its applicability to Hb and to soluble blood proteins in serum and plasma samples allows objective glycation assessment for all blood proteinsof interest with a single method. This may allow objective determination of antecedentglycemiccontrol for the previous 2-3 months (e.g., via GHb) and short-term diabetic control for the preceding 1-2 weeks [e.g., via glycatedplasma proteins (GPP), especially glycated albumin] in the same specimen.
To clinically evaluate the utffity of measurements of Glib and GPP by affinity HPLC in assessing durations of antecedent glycemia, we studied a diabetic outpatient population undergoing both intensive and conventional clinical intervention.
We evaluated these analytes for correlation with mean glucose concentrations for shortterm (1-3 weeks) and long-term (6 weeks) periods.
Patientsand Methods
Subjects. We studied 278 subjects, 70 of whom were diabetic. The 208 subjects evaluated to establish control ranges were considered nondiabetic on the basis of their known medical history and repeated fasting blood-glucose analysis.
The diabetic subjects were grouped according to treatment intervention.
Group I consisted of 30 non-insulin-independent diabetes mellitus (NIDDM) patients (16 women, 14 men, mean age 53 ± 3 years, range 34-69),consideredto be moderately uncontrolled (GHb 10%), for which clinical intervention consisted of dietary changes and (or) insulin adjustments to decrease mean weekly glucose significantly over 8 weeks. These patients were monitored with a home glucose-monitoring system with electronic log books as performed with insulin (e.g., Ultralentebased) or insulin-pump regimen. The correlations of GHb and GPP with the weekly, 2-, 3-, and 6-week glucose means were determined for Group I subjects and with 6-week glucose means for Group II subjects. All patients gave informed consent and the study was approved by the Clinical Research Practices
Committee of the Bowman Gray School of Medicine.
Sample prepara#{252}on.Whole blood collected by venipuncture with EDTA as anticoagulant was centrifuged at 1500g for 10 mm; the plasma was removed and diluted 10-fold with GPP diluent (Primus, Kansas City, MO); the packed erythrocytes were diluted with 200-fold Glib diluent containing an aqueous hemolysis reagent and preservative (Primus). The samples were diluted directly in the vials used for the assay.
Instrumentation. The Primus CLC33O high-performance liquid chromatograph determines both GHb and GPP by automated HPLC boronate affinity methods. Equipped with an ultraviolet/visible light detector, autosampler, computing integrator, and two disk drives, the system is controlled through automation software provided by Primus. Both the analytical system and the automation software are described in detail elsewhere (21).
HPLC analysis.
Sample vials were loaded into the autosainpler, identified as to sample type,and analyzed by the automation software. The analytical sequence is as follows: Whole-blood hemolysate (5 L) or diluted plasma (10 L) is automatically injected onto a boronate affinity column (Primus). The 0.5 x 5 cm glass analyticalcolumn used for the separation of GHb from other Hb species contains m-aminophenyl boronic acid covalently bound to a 10-tm-thick vinyl polymer solid support, producing
>1200
theoretical plates per column. Glycated species are retained by the column while nonglycated species (peak 1) are eluted through the column and detector with elution reagent 1 (mobile phase from injection to 0.2 miii): ammonium acetate buffer (250 mmol/L), sodium chloride (500 mmoIIL) magnesium chloride (30 mmolIL), ethanol (45 mldL), methanol (2.5 milL), isopropanol (2.5 milL), pH 9. Elution reagent 2 (0.2-1.3mm) contains a competing polyol designed to release the boronate-bound glycated protein fraction (peak 2). The reagent contains sodium chloride (150 mmol/L), ethanol (45 mLfL), methanol (2.5 mL/L), isopropanol (2.5 mL/L), and mannitol (100 mmol!L). Elution reagent 1 is then added (1.3-2.0 min) to prepare for the next sample sequence. There is -0.7-mm lag time between switching to each mobile phase and its arrival at the detector. All reagents were supplied by Primus.
The flow rate was 1.8 mL/min; the column oven was kept at 40#{176}C. GHb was detected at 413 nm, GPP at 280 nm. Quantification was by peak-area analysis with a calibration curve derived from calibrator samples. The computing integrator calculates the percentage of the glycated species by the following formula, as previously described (19): % glycated species = 100 [peak 1 area! (peak 1 area + peak 2 area)]. Intra-and interassay CVs were 1.2% and 2.1%, respectively (n = 10, mean =
5.7%).
Calibration. 
Results
The range of GHb results for the nondiabetics (n = 208, mean ± SD fasting glucose 4.6 ± 1.2 mmol/L) was 4.0-8.0% (mean ± SD 5.55 ± 0.74%). Using the 95th percentile as the upper limit, we determined the upper range of normal GHb for this assay to be 7.0%. The range of GPP results for nondiabetics was 13.4-25.0% (mean 19.2%; SD 2.2%), with the 95th percentile (upper range of normal) at 23.5%. Figure  1A represents the mean weekly concentrations of CBG, GHb, and GPP in the intensive intervention group. With use of repeated-measures analysis of variance, significant decreases in Glib (P <0.0001), GPP (P <0.003), and CBG (P <0.0001) were noted over time. As demonstrated in Fig. 1B , no major changes in GPP, mean CBG, or GHb were seen in Group II subjects, demonstrating relatively stable glycemia over the period of observation.
The mean weekly CBG decreases for the intensively intervened subjects (Group I) at weeks 1-8 were 15.7%, 12.3%, 6.7%, 5%, 9.1%, 5.8%, (ACBG) concentrations with the changes in Glib (iGHb) for this period to determine whether GHb could detect short-term glycemic changes. iCBG at the end of week 1 and week 2 correlated significantly with iXGHb at week 1 (r = 0.45, P <0.02) and week 2 (r = 0.57, P <0.002), but not with iCBG from weeks 3-8.
To determine the ability of Glib and GPP to monitor antecedent diabetic control, we correlated weekly means for CBG, Glib, and GPP from Group I subjects. Glib correlated significantly with the weekly, 2-week and 3-week mean blood glucose ( Fig. 2A-C and Table 1) , and with the mean 6-week glucose concentration in both Group I (r = 0.83, P <0.001) and Group II (r = 0.84, P <0.00 1) subjects (Table 1) , despite the weekly changes in glucose seen in Group I. GPP concentrations at each week of study correlated significantly with the weekly, 2-week, and 3-week mean CBGs in the Group I patients (Fig. 2D-F and Table 1 ). The 6-week mean CBG for Group I subjects also correlated significantly with the GPP (r = 0.49, P <0.001), although at a lower correlation than when compared with Group II (r = 0.64, P <0.001) ( Table 1) . Glycated albumin was determined by minicolumns for all Group I and Group II patients at baseline and correlated significantly with the GPP by automated affinity HPLC (r = 0.83, P <0.001). Glib correlated significantly with the GPP at baseline in Group I (r = 0.61, P <0.001), but by week 8 the correlation was no longer significant (r = 0.26). In Group II, Glib maintained good correlation with GPP at each 6-week cycle(r = 0.65-0.72, P <0.001).
Discussion
As would be expected, GHb determined by automated affinity HPLC correlates well with long-term glucose control in diabetic outpatients monitored at 6-week intervals. Despite weekly changes in mean blood glucose in our intensive intervention subjects, Glib, traditionally considered a marker only for long-term diabetic control, correlated significantly with the weekly, 2-week, 3-week, and 6-week mean glucose and demonstrated an ability to detect recent changes in glycemia. GPP correlated significantly with measured glycated albumin concentrations determined by boronate affinity minicolwnns and correlated best with the 1-3-week mean glucose, demonstrating validity as a measure of short-term glycemia.
Long-term prospective studies (e.g., 4) have demonstrated that the measurement of glycated blood protein markers as objective markers of antecedent glycemic control can predict the development of diabetic complications such as retinopathy, nephropathy, and neuropathy (1) (2) (3) (4) . Physicians are now encouraged to normalize the patient's glycemic profile while minimizing the side effects of intensive therapy (4). The reduction in glycation of blood proteins, secondary to a lowered mean blood glucose concentration, is postulated to decrease tissue accumulation of nonenzymatically attached glucose, thereby preventing the advanced glycation (i.e., protein cross-linking) thought to contribute to the tissue dysfunction (24-27). Therefore, the measurement of Glib as an objective marker for antecedent glycemic control has received renewed clinical interest.
Our data demonstrate that Glib determined by automated affinity HPLC is an excellent index of antecedent long-term diabetic control (i.e., 6 weeks), showing excellent correlation in both an intensively intervened and a relatively stable outpatient population at 6-week intervals. GPP primarily showed validity in monitoring short-term control in the acute intervention patients, and had decreased correlation with mean CBG when evaluated at 6-week intervals in this group. This suggests that the most appropriate antecedent glycemic window for GPP may be the preceding 1-3 weeks. However, in the Group II patients, GPP maintained high correlation with the mean outpatient glucose concentration over a 6-week interval. Group II did not have major changes in mean blood glucose, so the GPP would be expected to maintain excellent correlation with both mean CBG and GHb. However, GHb correlated with 1-, 2-, and 3-week mean glycemia, and the change in GHb concentrations, especially during the first weeks of therapy, correlated significantly with the change in mean glycemia. These findings cannot be attributed to inter- __________ and suggest that the GHb assay we used may provide the same clinical information as the GPP assay. Therefore, one may have little need to measure GPP if a highly precise Glib assay is available.
We note, however, that an acute decrease in glycemia in this report was accompanied by significant changes in an increased GHb (our patients were considered in poor control initially). Whether Glib at a normal or near-normal value on initial measurements can detect glycemic excursions as well as short-lived proteins do need to be addressed.
In conclusion, this boronate affinity HPLC method for the determination of Glib and GPP is rapid (run time <2 mm) and precise (CV s2%), and provides a valid objective measure to assess both short-and long-term antecedent control.
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